

klinisch-theoretische Abteilung "Klinische Pharmakologie"

Journalbeiträge

1. Bachus R, Neubert K, Roots I, Prudlo J, Brockmoller J, Ludolph AC (2003) Polymorphisms of toxifying and detoxifying hepatic enzymes in amyotrophic lateral sclerosis. *J NEUROL NEUROSUR PS*, 74(8): 1161.
2. Bauer S, Stormer E, Kirchheiner J, Michael C, Brockmoller J, Roots I (2003) Rapid and simple method for the analysis of nateglinide in human plasma using HPLC analysis with UV detection. *J PHARMACEUT BIOMED*, 31(3): 551-5.
3. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmoller J, Frotschl R, Kopke K, Gerloff T, Chernov JN, Roots I (2003) Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. *EUR J CLIN PHARMACOL*, 59(4): 303-12. Epub 2003 Jul 15.
4. Gashaw I, Kirchheiner J, Goldammer M, Bauer S, Seidemann J, Zoller K, Mrozikiewicz PM, Roots I, Brockmoller J (2003) Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics. *CLIN PHARMACOL THER*, 74(5): 448-57.
5. Gungor K, Ozkur M, Cascorbi I, Brockmoller J, Bekir N, Roots I, Aynacioglu AS (2003) Beta 2-adrenergic receptor polymorphism and susceptibility to primary congenital and primary open angle glaucoma. *EUR J CLIN PHARMACOL*, 59(7): 527-31. Epub 2003 Sep 12.
6. Hung RJ, Boffetta P, Brockmoller J, Butkiewicz D, Cascorbi I, Clapper ML, Garte S, Haugen A, Hirvonen A, Anttila S, Kalina I, Le Marchand L, London SJ, Rannug A, Romkes M, Salagovic J, Schoket B, Gaspari L, Taioli E (2003) CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. *CARCINOGENESIS*, 24(5): 875-82.
7. Johne A, Roots I, Brockmoller J (2003) A single nucleotide polymorphism in the human H-ras proto-oncogene determines the risk of urinary bladder cancer. *CANCER EPIDEM BIOMAR*, 12(1): 68-70.
8. Kaiser R, Hofer A, Grapengiesser A, Gasser T, Kupsch A, Roots I, Brockmoller J (2003) L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. *NEUROLOGY*, 60(11): 1750-5.
9. Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Mordt TE, Roots I, Brockmoller J (2003) Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. *PHARMACOGENETICS*, 13(10): 619-26.
10. Kirchheiner J, Kudlicz D, Meisel C, Bauer S, Meineke I, Roots I, Brockmoller J (2003) Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. *CLIN PHARMACOL THER*, 74(2): 186-94.
11. Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmoller J (2003) Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. *BRIT J CLIN PHARMACO*, 55(1): 51-61.
12. Kirchheiner J, Muller G, Meineke I, Wernecke KD, Roots I, Brockmoller J (2003) Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. *J CLIN PSYCHOPHARM*, 23(5): 459-66.
13. Kirchheiner J, Sasse J, Meineke I, Roots I, Brockmoller J (2003) Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity. *PHARMACOGENETICS*, 13(12): 721-8.
14. Kirchheiner J, Stormer E, Meisel C, Steinbach N, Roots I, Brockmoller J (2003) Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. *PHARMACOGENETICS*, 13(8): 473-80.
15. Meineke I, Turck D (2003) Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients. *BRIT J CLIN PHARMACO*, 55(1): 32-8.
16. Meisel C, Gerloff T, Kirchheiner J, Mrozikiewicz PM, Niewinski P, Brockmoller J, Roots I (2003) Implications of pharmacogenetics for individualizing drug treatment and for study design. *J MOL MED-JMM*, 81(3): 154-67. Epub 2003 Mar 15.
17. Schmidt H, Vormfelde SV, Walchner-Bonjean M, Klinder K, Freudenthaler S, Gleiter CH, Gundert-Remy U, Skopp G, Aderjan R, Fuhr U (2003) The role of active metabolites in dihydrocodeine effects. *INT J CLIN PHARM TH*, 41(3): 95-106.
18. Stormer E, Bauer S, Kirchheiner J, Brockmoller J, Roots I (2003) Simultaneous determination of celecoxib, hydroxycelecoxib, and carboxycelecoxib in human plasma using gradient reversed-phase liquid chromatography with ultraviolet absorbance detection. *J CHROMATOGR B*, 783(1): 207-12.
19. Taioli E, Gaspari L, Benhamou S, Boffetta P, Brockmoller J, Butkiewicz D, Cascorbi I, Clapper ML, Dolzan V, Haugen A, Hirvonen A, Husgafvel-Pursiainen K, Kalina I, Kremers P, Le Marchand L, London S, Rannug A, Romkes M, Schoket B, Seidegard J, Strange RC, Stucker I, To-Figueras J, Garte S (2003) Polymorphisms in CYP1A1, GSTM1, GSTT1 and lung cancer below the age of 45 years. *INT J EPIDEMIOL*, 32(1): 60-3.

klinisch-theoretische Abteilung "Klinische Pharmakologie"

20. Tremblay PB, Kaiser R, Sezer O, Rosler N, Schelenz C, Possinger K, Roots I, Brockmoller J (2003) Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. *J CLIN ONCOL*, 21(11): 2147-55.
21. Vormfelde SV, Burckhardt G, Zirk A, Wojnowski L, Brockmoller J (2003) Pharmacogenomics of diuretic drugs: data on rare monogenic disorders and on polymorphisms and requirements for further research. *PHARMACOGENOMICS*, 4(6): 701-34.